C4 Therapeutics, Inc. (CCCC)
CCCC Stock Price Chart
Explore C4 Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze CCCC price movements and trends.
CCCC Company Profile
Discover essential business fundamentals and corporate details for C4 Therapeutics, Inc. (CCCC) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
2 Oct 2020
Employees
110.00
Website
https://www.c4therapeutics.comCEO
Andrew J. Hirsch
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
CCCC Financial Timeline
Browse a chronological timeline of C4 Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 30 Oct 2025
EPS estimate is -$0.43.
Earnings released on 7 Aug 2025
EPS came in at -$0.37 surpassing the estimated -$0.38 by +2.63%, while revenue for the quarter reached $6.46M , missing expectations by -4.96%.
Earnings released on 7 May 2025
EPS came in at -$0.37 surpassing the estimated -$0.48 by +22.92%, while revenue for the quarter reached $7.24M , beating expectations by +104.46%.
Earnings released on 27 Feb 2025
EPS came in at -$0.49 falling short of the estimated -$0.44 by -11.36%, while revenue for the quarter reached $5.18M , beating expectations by +55.31%.
Earnings released on 31 Oct 2024
EPS came in at -$0.35 surpassing the estimated -$0.40 by +12.50%, while revenue for the quarter reached $15.36M , beating expectations by +360.86%.
Earnings released on 1 Aug 2024
EPS came in at -$0.26 surpassing the estimated -$0.37 by +29.73%, while revenue for the quarter reached $12.01M , beating expectations by +151.00%.
Earnings released on 8 May 2024
EPS came in at -$0.41 matching the estimated -$0.41, while revenue for the quarter reached $3.04M , missing expectations by -62.48%.
Earnings released on 22 Feb 2024
EPS came in at -$0.68 falling short of the estimated -$0.67 by -1.49%, while revenue for the quarter reached $3.26M , beating expectations by +2.23%.
Earnings released on 1 Nov 2023
EPS came in at -$0.55 surpassing the estimated -$0.65 by +15.38%, while revenue for the quarter reached $11.07M , beating expectations by +102.78%.
Earnings released on 8 Aug 2023
EPS came in at -$0.73 surpassing the estimated -$0.74 by +1.35%, while revenue for the quarter reached $2.66M , missing expectations by -58.63%.
Earnings released on 4 May 2023
EPS came in at -$0.71 surpassing the estimated -$0.78 by +8.97%, while revenue for the quarter reached $3.76M , missing expectations by -31.15%.
Earnings released on 23 Feb 2023
EPS came in at -$0.76 falling short of the estimated -$0.72 by -5.56%, while revenue for the quarter reached $2.85M , missing expectations by -71.09%.
Earnings released on 3 Nov 2022
EPS came in at -$0.65 matching the estimated -$0.65, while revenue for the quarter reached $6.75M , missing expectations by -20.07%.
Earnings released on 4 Aug 2022
EPS came in at -$0.56 surpassing the estimated -$0.68 by +17.65%, while revenue for the quarter reached $13.83M , beating expectations by +81.13%.
Earnings released on 5 May 2022
EPS came in at -$0.65 falling short of the estimated -$0.61 by -6.56%, while revenue for the quarter reached $7.65M , missing expectations by -1.94%.
Earnings released on 24 Feb 2022
EPS came in at -$0.31 surpassing the estimated -$0.59 by +47.46%, while revenue for the quarter reached $20.08M , beating expectations by +171.02%.
Earnings released on 10 Nov 2021
EPS came in at -$0.51 surpassing the estimated -$0.60 by +15.00%, while revenue for the quarter reached $8.50M , missing expectations by -13.04%.
Earnings released on 11 Aug 2021
EPS came in at -$0.51 surpassing the estimated -$0.60 by +15.00%, while revenue for the quarter reached $9.78M , beating expectations by +62.48%.
Earnings released on 13 May 2021
EPS came in at -$0.49 surpassing the estimated -$0.63 by +22.22%, while revenue for the quarter reached $7.43M , missing expectations by -18.18%.
Earnings released on 11 Mar 2021
EPS came in at -$0.04 surpassing the estimated -$0.53 by +92.45%, while revenue for the quarter reached $8.26M .
Earnings released on 12 Nov 2020
EPS came in at -$17.55 falling short of the estimated -$0.79 by -2.12K%, while revenue for the quarter reached $8.45M , missing expectations by -94.50%.
Earnings released on 2 Oct 2020
EPS came in at -$0.26 , while revenue for the quarter reached $9.67M .
CCCC Stock Performance
Access detailed CCCC performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.